Trial reportRespiratory research2020
Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial.
Trial report in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02622022 (Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Effect of breathing exercises on patients with interstitial lung disease: A systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Opioid Prescription Method for Breathlessness Due to Non-Cancer Chronic Respiratory Diseases: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Cardiorespiratory responses to muscle metaboreflex activation in fibrosing interstitial lung disease.Experimental physiology · 2022Trial
- Non-pharmacological Management of Fibrosing Interstitial Lung Diseases.Tuberculosis and respiratory diseases · 2026Article
- Palliative care in systemic sclerosis: incorporating advance care planning into longitudinal care.Journal of scleroderma and related disorders · 2026Review
- TheJournal of clinical medicine · 2024Review
- Patient-centered care in pulmonary fibrosis: access, anticipate, and act.Respiratory research · 2024Review
- Validation of a Novel Clinical Dyspnea Scale - A Retrospective Pilot Study.The American journal of hospice & palliative care · 2024Article
- Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.Respirology (Carlton, Vic.) · 2024Article
- Holistic management of patients with progressive pulmonary fibrosis.Breathe (Sheffield, England) · 2023Review
- Effectiveness and safety of opioids for dyspnea in patients with lung cancer: secondary analysis of multicenter prospective observational study.Translational lung cancer research · 2022Article
- End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation.Respiratory research · 2022Article
- Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study.Respiratory research · 2022Article
- Acute exacerbation of interstitial lung disease associated with rheumatic disease.Nature reviews. Rheumatology · 2022Review
- Article
- Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?Frontiers in medicine · 2021Review
- Palliative Care Support Improves Quality of Life of Patients with Fibrotic Interstitial Lung Disease.Palliative medicine reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients suffering from fibrotic interstitial lung diseases (fILD) have a poor prognosis and a high symptom burden. Palliative treatment includes relief of symptoms such as breathlessness. There is no evidence-based treatment for chronic breathlessness but opioids are often used despite concerns due to the hypothetical risk of respiratory depression. This study investigated the effect of oral morphine drops in patients with fILD on chronic breathlessness and safety.
methodsIn a double-blinded placebo-controlled study, 36 patients with fILD were randomised to either four daily doses of 5 mg of oral morphine drops or placebo for 1 week. Endpoints and safety parameters were obtained at baseline, at follow-up after 1 h and 1 week.
resultsThe primary endpoint, the visual analogue score (VAS) of dyspnea was reduced by 1.1 ± 0.33 cm in the morphine group at follow-up compared to baseline (P < 0.01), whereas the reduction was 0.35 ± 0.47 cm in the placebo group. However, the difference between the two groups was not statistically significant (p = 0.2). Oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test. More patients treated with morphine reported constipation, nausea and confusion.
conclusionOral administration of morphine drops, 20 mg a day, in patients with fILD did not significantly reduce dyspnea VAS score during 1 week compared to placebo. Oral morphine did not induce respiratory depression, but was related to an increased risk of constipation, nausea and confusion.
trial registrationThe trial is registered in clinicaltrials.gov (Identifier: NCT02622022 ). Registered 4 December 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.